Synthomer Offloads Acrylate Monomers Unit to Mutares in Strategic Portfolio Shift

Synthomer plc has inked a deal to sell its Acrylate Monomers division, housed within Synthomer a.s. in the Czech Republic, to Mutares SE & Co. KGaA, a German-listed private equity firm specializing in industrial turnarounds. This transaction covers the manufacturing hub in Sokolov, where roughly 300 employees focus on producing acrylic acid and related monomers.

The Acrylate Monomers unit caters primarily to the European merchant market but also supports Synthomer's internal operations by supplying acrylic monomers and producing acrylic dispersions. Notably, these internal supply agreements will remain intact despite the ownership change, ensuring continuity for Synthomer's downstream activities.

Strategically, this sale marks a significant step in Synthomer's reshaping of its portfolio. The division falls under the Health & Protection and Performance Materials segment and is known for its cyclical demand and capital-intensive nature. Importantly, it is Synthomer's last upstream business, previously flagged as non-core during a 2022 strategic review.

CEO Michael Willome highlighted the move as part of an ongoing effort to simplify the company's structure and pivot toward higher-margin specialty chemicals. By shedding the Acrylate Monomers business, Synthomer aims to reduce exposure to volatile, resource-heavy markets and sharpen its focus where it holds leadership positions.

For Mutares, well-versed in revamping industrial entities, acquiring the Acrylate Monomers unit presents an opportunity to leverage its operational expertise. The firm's experience positions it to guide this business through its next growth phase within the European chemical sector.

While the sale exits Synthomer from an upstream capital-intensive chemical segment, it retains a foothold in specialty markets through its remaining divisions. This transaction could affect supply-chain dynamics given the ongoing supply commitments but leaves the group's downstream footprint stable.

The move also underscores a broader industry tendency where chemical companies streamline operations to concentrate on more specialized, less cyclical areas. Such restructurings often aim to boost profitability and reduce vulnerability to commodity price swings.

As leadership refines its portfolio, the market will be watching how Synthomer balances shedding capital-heavy assets with investing in growth-driven specialty chemicals. Meanwhile, Mutares's approach to integrating and revitalizing the newly acquired unit could provide insight into private equity's role in the European industrial sector.